| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/13/2011 | EP2343069A1 Heterocyclic aspartyl protease inhibitors |
| 07/13/2011 | EP2343068A2 Treatment of length dependent neuropathy |
| 07/13/2011 | EP2343067A1 Pharmaceutical composition for the eradication of helicobacter pylori and preparation method thereof |
| 07/13/2011 | EP2343066A1 Therapeutic agent for hepatitis c |
| 07/13/2011 | EP2343065A1 The pharmaceutical composition containing ferulic acid and matrine compounds, the preparation and the use thereof |
| 07/13/2011 | EP2343064A1 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| 07/13/2011 | EP2343063A1 Pharmaceutical preparations comprising a COS releasing compound |
| 07/13/2011 | EP2343062A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 07/13/2011 | EP2343060A1 Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers |
| 07/13/2011 | EP2343058A2 A pharmaceutical formulation containing olanzapine |
| 07/13/2011 | EP2343057A1 Method and composition for administering an NMDA receptor antagonist to a subject |
| 07/13/2011 | EP2343056A1 Producing stable adefovir dipivoxil solid dispersions |
| 07/13/2011 | EP2343055A1 Pharmaceutical compositions of pregabalin |
| 07/13/2011 | EP2343054A1 Pellets and microparticles of pravastatin sodium and a process of making them |
| 07/13/2011 | EP2343051A2 Anti-cancer formulation |
| 07/13/2011 | EP2343048A2 Stabilized and preserved ketotifen ophthalmic compositions |
| 07/13/2011 | EP2343044A1 Cosmetic composition for sensitive skins |
| 07/13/2011 | EP2343038A1 Dermatological compositions comprising a combination of peroxidized lipids and zinc for use amongst others in the treatment of herpes |
| 07/13/2011 | EP2342979A2 Composition for improving membrane composition and functioning of cells |
| 07/13/2011 | EP2342978A2 Composition for improving membrane composition and functioning of cells |
| 07/13/2011 | EP2342977A2 Composition for improving membrane composition and functioning of cells |
| 07/13/2011 | EP2342976A2 Composition for improving membrane composition and functioning of cells |
| 07/13/2011 | EP2342975A2 Composition for improving membrane composition and functioning of cells |
| 07/13/2011 | EP2342974A2 Composition for improving membrane composition and functioning of cells |
| 07/13/2011 | EP2342341A1 Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells |
| 07/13/2011 | EP2342340A1 Rna interference in skin indications |
| 07/13/2011 | EP2342335A1 Novel gene cluster |
| 07/13/2011 | EP2342205A1 Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| 07/13/2011 | EP2342203A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 07/13/2011 | EP2342202A1 Azaindole derivative |
| 07/13/2011 | EP2342201A1 Indole derivatives as crth2 receptor antagonists |
| 07/13/2011 | EP2342200A2 Compounds which selectively modulate the cb2 receptor |
| 07/13/2011 | EP2342199A2 Compounds which selectively modulate the cb2 receptor |
| 07/13/2011 | EP2342198A1 Salts of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide |
| 07/13/2011 | EP2342195A2 Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt |
| 07/13/2011 | EP2342194A1 Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics |
| 07/13/2011 | EP2342192A2 Nicotinic acetylcholine receptor ligands and the uses thereof |
| 07/13/2011 | EP2342191A1 Aromatic nitrogen-containing 6-membered ring compounds and their use |
| 07/13/2011 | EP2342190A1 Bicyclic kinase inhibitors |
| 07/13/2011 | EP2342189A2 Selective estrogen receptor modulator for the treatment of osteoarthritis |
| 07/13/2011 | EP2342188A1 Chromenone analogs as sirtuin modulators |
| 07/13/2011 | EP2342187A1 Glycoside derivatives and uses thereof |
| 07/13/2011 | EP2342186A2 Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor |
| 07/13/2011 | EP2342185A1 Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine |
| 07/13/2011 | EP2342182A1 Isoquinolinone derivatives as nk3 antagonists |
| 07/13/2011 | EP2342181A1 Novel urea and thiourea derivatives |
| 07/13/2011 | EP2342178A1 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| 07/13/2011 | EP2342177A1 Novel potassium channel blockers |
| 07/13/2011 | EP2342175A1 Nitric oxide releasing amino acid ester compound, composition and method of use |
| 07/13/2011 | EP2342173A1 Salicylic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors |
| 07/13/2011 | EP2341953A2 Hydrogels for vocal cord and soft tissue augmentation and repair |
| 07/13/2011 | EP2341943A2 Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| 07/13/2011 | EP2341937A1 Composition for treating disease |
| 07/13/2011 | EP2341915A1 Phosphorylated dendrimers as antiinflammatory drugs |
| 07/13/2011 | EP2341914A2 Modulation of toll-like receptor 3 expression by antisense oligonucleotides |
| 07/13/2011 | EP2341913A1 Method of enhancing tgf-beta signalling |
| 07/13/2011 | EP2341912A2 Method of treatment of attention deficit/hyperactivity disorder (adhd) |
| 07/13/2011 | EP2341911A2 Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| 07/13/2011 | EP2341910A1 Immediate release dosage forms of sodium oxybate |
| 07/13/2011 | EP2341909A1 Novel substituted azabenzoxazoles |
| 07/13/2011 | EP2341908A1 Individual 5-fluorouracile dose optimization in folfiri treatment |
| 07/13/2011 | EP2341907A1 Synergistic combinations of a macrocyclic inhibitor of hcv and a nucleoside |
| 07/13/2011 | EP2341906A2 Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| 07/13/2011 | EP2341905A1 Sustained release formulations using non-aqueous carriers |
| 07/13/2011 | EP2341904A1 Methods for treatment of multiple sclerosis |
| 07/13/2011 | EP2341903A1 Cannabinoids for use in treating or preventing cognitive impairment and dementia |
| 07/13/2011 | EP2341902A1 Glucoside derivatives and uses thereof as sglt inhibitors |
| 07/13/2011 | EP2341901A1 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion |
| 07/13/2011 | EP2341900A1 A medicinal product and treatment |
| 07/13/2011 | EP2341899A1 Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
| 07/13/2011 | EP2341895A2 Hyaluronic acid cryogel - compositions, uses, processes for manufacturing |
| 07/13/2011 | EP2341891A2 Monoester of n-undecylenoyl phenylalanine and polyol, method for preparing same, and use of said esters as a skin lightening agent |
| 07/13/2011 | EP2341886A1 Antimicrobial n-chlorinated compositions |
| 07/13/2011 | EP2341785A1 Nutrition composition containing omega-3 fatty acids and mcts |
| 07/13/2011 | EP2341784A1 Nutritional compositions with coated lipid globules |
| 07/13/2011 | EP2341777A1 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions |
| 07/13/2011 | EP2341776A1 Compounds, compositions and methods comprising imidazole and triazole derivatives |
| 07/13/2011 | EP2341775A1 Inhibitors of janus kinases |
| 07/13/2011 | EP2341774A1 Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| 07/13/2011 | EP2341773A1 Pharmaceutical compositions of atorvastatin |
| 07/13/2011 | EP2341772A1 Synthesis of decitabine |
| 07/13/2011 | EP2341771A1 Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment |
| 07/13/2011 | EP2252263B1 Galenic form for the oral transmucosal delivery of triptans |
| 07/13/2011 | EP2200985B1 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| 07/13/2011 | EP2182917B1 A gastroretentive composition on the basis of a water-soluble reaction product from a vinyl group- containing precursor |
| 07/13/2011 | EP2146750B1 Stabilized suspension |
| 07/13/2011 | EP2143438B1 Compositions and methods for the diagnosis and treatment of tumors |
| 07/13/2011 | EP2137147B1 Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer |
| 07/13/2011 | EP2102197B1 5-([1,3,4]oxadiazol-2-yl)-1h-indazol and 5-([1,3,4]thiadiazol-2-yl)-1h-indazol derivatives as sgk inhibitors for the treatment of diabetes |
| 07/13/2011 | EP2086532B1 Use for treating obesity and diabetes |
| 07/13/2011 | EP2034977B1 Use of opioid receptor antagonists |
| 07/13/2011 | EP1984001B1 Fixed-dose association of phytate and zinc |
| 07/13/2011 | EP1975158B1 Novel pyrrole derivatives with histone deacetylase inhibitor activity |
| 07/13/2011 | EP1974731B1 Morphinan derivatives for use as antitussive agents |
| 07/13/2011 | EP1965764B1 Self-emulsifying formulations of cetp inhibitors |
| 07/13/2011 | EP1931683B1 Fused tricyclic mglur1 antagonists as therapeutic agents |
| 07/13/2011 | EP1896000B1 Versatile high load concentrate compositions comprising metaflumizone for control of ecto-parasites |
| 07/13/2011 | EP1885684B1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the beta-2 adrenergic receptor |
| 07/13/2011 | EP1852434B1 Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity |
| 07/13/2011 | EP1844032B1 N-hydroxyamide derivatives and use thereof |